Vir Biotechnology (NASDAQ:VIR) Receives Buy Rating from HC Wainwright

Vir Biotechnology (NASDAQ:VIR - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $110.00 price target on the stock. HC Wainwright also issued estimates for Vir Biotechnology's Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.81) EPS and Q4 2026 earnings at ($0.77) EPS.

A number of other analysts have also commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Thursday, February 27th. Leerink Partners raised their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Barclays lowered their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $35.67.

Remove Ads

Vir Biotechnology Stock Performance

NASDAQ VIR traded up $0.28 during trading hours on Friday, reaching $8.20. The company's stock had a trading volume of 1,556,977 shares, compared to its average volume of 2,442,124. The stock has a market cap of $1.13 billion, a PE ratio of -2.09 and a beta of 0.64. The company's 50-day moving average is $9.47 and its two-hundred day moving average is $8.49. Vir Biotechnology has a fifty-two week low of $6.56 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to analysts' expectations of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Equities analysts expect that Vir Biotechnology will post -3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director George A. Scangos sold 10,964 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the sale, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Verneuil Vanina De sold 7,373 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares in the company, valued at $726,264.40. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,859 shares of company stock valued at $326,458 over the last quarter. Company insiders own 15.60% of the company's stock.

Institutional Investors Weigh In On Vir Biotechnology

Several large investors have recently made changes to their positions in the business. Blue Trust Inc. increased its holdings in Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock valued at $30,000 after purchasing an additional 2,351 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Vir Biotechnology by 23.9% in the third quarter. Victory Capital Management Inc. now owns 81,269 shares of the company's stock worth $609,000 after buying an additional 15,696 shares during the period. Quest Partners LLC grew its stake in shares of Vir Biotechnology by 171.4% in the third quarter. Quest Partners LLC now owns 34,455 shares of the company's stock valued at $258,000 after buying an additional 21,760 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Vir Biotechnology during the 3rd quarter valued at about $191,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Vir Biotechnology by 13.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company's stock valued at $8,496,000 after buying an additional 136,087 shares during the period. Institutional investors and hedge funds own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).